| Literature DB >> 29250445 |
G Kalender1, Milan Lisy2, U A Stock3, A Endisch4, A Kornberger5.
Abstract
Patients who undergo endovascular repair of aortic aneurysms (EVAR) require life-long surveillance because complications including, in particular, endoleaks, aneurysm rupture, and graft dislocation are diagnosed in a certain share of the patient population and may occur at any time after the original procedure. Radiation exposure in patients undergoing EVAR and post-EVAR surveillance has been investigated by previous authors. Arriving at realistic exposure data is essential because radiation doses resulting from CT were shown to be not irrelevant. Efforts directed at identification of factors impacting the level of radiation exposure in both the course of the EVAR procedure and post-EVAR endovascular interventions and CTAs are warranted as potentially modifiable factors may offer opportunities to reduce the radiation. In the light of the risks found to be associated with radiation exposure and considering the findings above, those involved in EVAR and post-EVAR surveillance should aim at optimal dose management.Entities:
Year: 2017 PMID: 29250445 PMCID: PMC5700475 DOI: 10.1155/2017/9763075
Source DB: PubMed Journal: Int J Vasc Med ISSN: 2090-2824
Patient characteristics and details on occurrences during the observation period.
| Patient characteristics, complications, and secondary surgical/endovascular interventions | ||
|---|---|---|
| Total number of patients | 59 | |
| Male versus female patients | 55 (93.2%) | 4 (6.8%) |
| Emergent versus elective EVAR | 3 (5%) | 56 (95%) |
| Mean age at the date of implantation | 70 yrs | (41–83 yrs) |
| Mean body mass index | 28 ± 4.3 kg/m2. | |
| Observation period terminated by non-EVAR related death | 8 (13.6%) | |
| Lost to follow-up | 2 (3.4%) | |
| Compliance versus noncompliance with the surveillance schedule | 36 (61%) | 23 (39%) |
| Open surgical correction procedures | 2 (3.4%) | |
| (i) Aortorenal bypass grafting for renal artery occlusion | 1 (1.7%) | |
| (ii) Explantation of a migrated stent graft and implantation of a bifurcated vascular graft | 1 (1.7%) | |
| Long-term corticosteroid treatment for suspected periprosthetic inflammatory reaction | 1 (1.7%) | |
| Endoleak (median persistence 222 days (IQR 66–787 days)) | 22 (37.3%) | |
| Primary endoleak (i.e., occurring within 30 days from EVAR), all classified as type II | 19 (32.2%) | |
| (i) Permanent | 4 (21.0%) | |
| (ii) Treated by endovascular intervention | 3 (15.8%) | |
| (iii) Spontaneous resolution (81% resolved during the first year post-EVAR) | 12 (63.2%) | |
| Secondary endoleak (i.e., occurring more than 30 days from EVAR) | 3 (5%) | |
| (i) Type II endoleak diagnosed 7 weeks after EVAR, death for nonaneurysm related causes | 1 (1.7%) | |
| (ii) Type II endoleak diagnosed 15 weeks after EVAR, spontaneous shrinkage of the aneurysm sac, no interventional or surgical correction but close surveillance | 1 (1.7%) | |
| (iii) Type I endoleak resulting from graft dislocation 3 years after EVAR, treated by open surgical repair | 1 (1.7%) | |
| Secondary endovascular procedures | 11 in 9 patients | |
| (i) Minimum/maximum period from EVAR to secondary endovascular procedure | 1 day/3.3 years | |
| (ii) Fibrinolysis, angioplasty, and/or stent angioplasty for graft limb occlusion | 5/11 | |
| (iii) Embolization of endoleaks | 3/11 | |
| (iv) Stent angioplasty for renal artery stenosis | 2/11 | |
| (v) Stent angioplasty for iliac artery stenosis | 1/11 | |
Effective doses from CTA and interventional procedures [in mSv].
| Effective doses from CTA and endovascular procedures [in mSv] | ||||||
|---|---|---|---|---|---|---|
| Min. ED | 1st | Median ED | 3rd | Max. |
| |
| CTA | 3.0 | 19.7 | 24.5 | 30.3 | 60.3 | |
| Native phase | 0.9 | 2.9 | 4.5 | 5.6 | 18.8 | |
| Arterial phase | 1.9 | 9.6 | 12.7 | 15.7 | 27.3 | |
| Late venous phase | 2.6 | 7.7 | 09.6 | 12.4 | 23.4 | |
|
| ||||||
| Mono- or biphasic CTA versus | 17.6 | |||||
| Triphasic CTA | 26.6 | <0.001 | ||||
|
| ||||||
| CTA pelvis/abdomen versus | 23.8 | |||||
| CTA pelvis/abdomen/thorax | 26.4 | 0.012 | ||||
|
| ||||||
| EVAR | 3.6 | 14.3 | 23.2 | 40.8 | 109.2 | |
|
| ||||||
| EVAR in normal weight patient versus | 13.4 | |||||
| EVAR in overweight patient versus | 18.5 | |||||
| EVAR in obese patient | 45.7 | <0.001 | ||||
|
| ||||||
| Secondary endovascular procedures | 2.6 | 13.6 | 20.8 | 25.5 | 60.7 | |
Figure 1Distribution of the study population over the WHO body mass classes, with dotted lines separating “underweight/normal weight,” “overweight,” and “obese.”
Figure 2Correlation between ED from CTA [in mSv] and body mass index [in kg/m2].
Figure 3EDs [in mSv] from triphasic CTA scans performed on the 5 scanner types employed most frequently.
Figure 4Correlation between fluoroscopy time [in minutes] and ED [in mSv] from the EVAR procedure.
Figure 5Correlation between body mass index [in kg/m2] and ED [in mSv] from the EVAR procedure.
Figure 6Density curves for the ED delivered to the three WHO BMI categories during EVAR.
Figure 7No correlation is identified between the fluoroscopy time and the body mass index.
Figure 8Cumulative ED [in mSv] during the first-year post-EVAR, shown by body mass index categories, with the width of the box plots adjusted to the number of patients per category.